BCL-6/NN
and/CC
the/DT
molecular/JJ
pathogenesis/NN
of/IN
B-cell/NN
lymphoma/NN
./.

The/DT
results/NNS
presented/VBN
identify/VBP
the/DT
first/JJ
genetic/JJ
lesion/NN
associated/VBN
with/IN
DLCL/NN
,/,
the/DT
most/RBS
clinically/RB
relevant/JJ
form/NN
of/IN
NHL/NN
./.
=====
Although/IN
no/DT
proof/NN
yet/RB
exists/VBZ
of/IN
a/DT
role/NN
for/IN
these/DT
lesions/NNS
in/IN
DLCL/NN
pathogenesis/NN
,/,
the/DT
feature/NN
of/IN
the/DT
BCL-6/NN
gene/NN
product/NN
,/,
its/PRP$
specific/JJ
pattern/NN
of/IN
expression/NN
in/IN
B/NN
cells/NNS
,/,
and/CC
the/DT
clustering/NN
of/IN
lesions/NNS
disrupting/VBG
its/PRP$
regulatory/JJ
domain/NN
strongly/RB
suggest/VBP
that/IN
deregulation/NN
of/IN
BCL-6/NN
expression/NN
may/MD
contribute/VB
to/TO
DLCL/NN
development/NN
./.
=====
A/DT
more/RBR
precise/JJ
definition/NN
of/IN
the/DT
role/NN
of/IN
BCL-6/NN
in/IN
normal/JJ
and/CC
neoplastic/JJ
B-cell/NN
development/NN
is/VBZ
the/DT
goal/NN
of/IN
ongoing/JJ
study/NN
of/IN
transgenic/JJ
mice/NNS
engineered/VBN
either/CC
to/TO
express/VB
BCL-6/NN
under/IN
heterologous/JJ
promoters/NNS
or/CC
lacking/VBG
BCL-6/NN
function/NN
due/JJ
to/TO
targeted/VBN
deletions/NNS
./.
=====
In/IN
addition/NN
to/TO
contributing/VBG
to/TO
the/DT
understanding/NN
of/IN
DLCL/NN
pathogenesis/NN
,/,
the/DT
identification/NN
of/IN
BCL-6/NN
lesions/NNS
may/MD
have/VB
relevant/JJ
clinical/JJ
implications/NNS
./.
=====
DLCL/NN
represent/VBP
a/DT
heterogeneous/JJ
group/NN
of/IN
neoplasms/NNS
which/WDT
are/VBP
treated/VBN
homogeneously/RB
despite/IN
the/DT
fact/NN
that/IN
only/RB
50/CD
%/NN
of/IN
patients/NNS
experience/VBP
long-term/JJ
disease-free/JJ
survival/NN
(/(
Schneider/NNP
et/FW
al./FW
1990/CD
)/)
./.
=====
The/DT
fact/NN
that/IN
BCL-6/NN
rearrangements/NNS
identify/VBP
biologically/RB
and/CC
clinically/RB
distinct/JJ
subsets/NNS
of/IN
DLCL/NN
suggests/VBZ
that/IN
these/DT
lesions/NNS
may/MD
be/VB
useful/JJ
as/IN
markers/NNS
in/IN
selection/NN
of/IN
differential/JJ
therapeutic/JJ
strategies/NNS
based/VBN
on/IN
different/JJ
risk/NN
groups/NNS
./.
=====
Furthermore/RB
,/,
the/DT
BCL-6/NN
rearrangements/NNS
can/MD
be/VB
used/VBN
to/TO
identify/VB
and/CC
monitor/VB
the/DT
malignant/JJ
clone/NN
with/IN
sensitive/JJ
PCR-based/JJ
techniques/NNS
./.
=====
Since/IN
clinical/JJ
remission/NN
has/VBZ
been/VBN
observed/VBN
in/IN
a/DT
significant/JJ
fraction/NN
of/IN
DLCL/NN
cases/NNS
,/,
these/DT
markers/NNS
may/MD
serve/VB
as/IN
critical/JJ
tools/NNS
for/IN
sensitive/JJ
monitoring/NN
of/IN
minimal/JJ
residual/JJ
disease/NN
and/CC
early/JJ
diagnosis/NN
of/IN
relapse/NN
(/(
Gribben/NNP
et/FW
al./FW
1993/CD
)/)
./.